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INTRODUCTION
Fabry disease (OMIM #301500) is an X-linked lysosomal
storage disorder caused by a deficiency of  -galactosidase A
(EC 3.2.1.22) (1). Progressive systemic deposition of globo-
triaosylceramide (GL-3) in podocytes causes proteinuria. Depo-
sitionin cardiomyocytes causes cardiac hypertrophy, and depo-
sition in vascular endothelial cells, in pericytes, and in smooth
muscle cells of the vascular system leads to ischemia and infarc-
tion. GL-3 accumulates in lysosomes of the vascular endothe-
lial, smooth muscle cells, epithelial, perithelial, reticuloendothe-
lial, myocardial, ganglion, and perineural cells (2). Deposition
of GL-3 occurs throughout the nephrons and renal vasculature,
leading to progressive glomerular injury associated with mesan-
gial widening and segmental and global glomerulosclerosis
(3). Early symptoms of Fabry disease include acroparesthesias,
angiokeratoma, and corneal opacities (4). In elderly patients,
accumulation of glycolipid progresses to chronic renal failure
and stroke. Death in the fifth decade was the usual common
outcome in affected males before the advent of dialysis and
transplantation (5). Female heterozygous carriers are usually
asymptomatic, but can be affected with a wide spectrum of
clinical abnormalities because of random X-chromosomal inac-
tivation, generally at a later age than affected males (6). Atyp-
ical variants of hemizygous Fabry disease were found among
patients who manifested with unexplained left ventricular
hypertrophy (7). Most non-classical variants with attenuated
disease do not have endothelial glycosphingolipid deposition,
do not develop renal failure and, after living a normal lifespan,
might die due to late cardiac manifestations of the disease.
Following Gaucher disease, Fabry disease is the second most
common lysosomal storage disorder with an estimated fre-
quency of 1 in 117,000 live births. The prevalence in males is
estimated as 1:40,000 to 60,000 (2, 8). The register contains
data on 8 classical male patients and 3 female symptomatic
carriers in this study. However, the precise prevalence of Fabry
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Short-Term Efficacy of Enzyme Replacement Therapy in Korean
Patients with Fabry Disease
Fabrazyme has been widely used for treatment of Fabry disease since its approval
by the U.S. Food and Drug Administration in 2003. This study was undertaken to
assess the short-term efficacy and safety of enzyme replacement therapy (ERT)
for Fabry disease in Korea. Eight male patients and three female symptomatic car-
riers aged 13 to 48 yr were included. Fabrazyme was administered by intravenous
infusion at a dose of 1 mg/kg every 2 weeks. Plasma and urine globotriaosylce-
ramide (GL-3) levels, serum creatinine, creatinine clearance, and 24-hr urine pro-
tein levels were measured every 3 months. Kidney biopsies, ophthalmologic exams,
and pure tone audiometry were performed before and 1 yr after ERT. Kidney func-
tion, including serum creatinine, creatinine clearance, and the 24-hr urine protein
level, remained stable during ERT. Plasma and urine GL-3 levels were reduced
within 3 to 6 months of ERT initiation. Microvascular endothelial deposits of GL-3
were decreased from renal biopsy specimens after 1 yr of treatment. The severity
of sensorineural hearing loss and tinnitus did not improve after ERT. ERT is safe
and effective in stabilizing renal function and clearing microvascular endothelial
GL-3 from kidney biopsy specimen in Korean patients with Fabry disease.
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Accepted : 13 August 2007disease is unknown in Korea. It is quite possible that the num-
ber of atypically symptomatic patients with renal or cardiac
variants of Fabry disease might be greater than current esti-
mates (9).
After approval of Fabrazyme
� (Genzyme Corp., Cambridge,
MA, U.S.A.) by the European Agency for the Evaluation of
Medicinal Products in 2001 and the U.S. Food and Drug Ad-
ministration in 2003, it has been widely used for treatment of
Fabry disease. Phase 1 and 2 trials with recombinant  -galac-
tosidase A have demonstrated enzyme replacement therapy
(ERT) is safe and effective in clearing the plasma and endothe-
lial deposits of GL-3 from target tissues (10). Several clinical
trials have shown that ERT in Fabry disease is efficacious in
decreasing pain, stabilizing renal function, and clearing gly-
colipids stored in the lysosomes (11, 12). This study was under-
taken to investigate the short-term clinical efficacy of ERT
for 8 classical male patients and 3 symptomatic female car-
riers with Fabry disease in Korea.
MATERIALS AND METHODS
Patients
To date, 11 patients (8 classical male patients and 3 symp-
tomatic female carriers) have been under ERT after obtaining
informed consent. The patients were between 13 and 48 yr
of age (mean 28.6±11.89 yr). All patients were examined
for changes in angiokeratoma and other changes in clinical
symptoms at each visit. Patients’ ophthalmologic status was
evaluated with a complete assessment that included a slit-lamp
examination every 6 months by an ophthalmologist. Electro-
cardiogram and pure tone audiometry were also performed
before ERT and every 6 months during treatment. Renal func-
tion was evaluated by measuring serum creatinine, creatinine
clearance, and 24-hr urine protein levels every 3 months. No
patients received any concomitant medication, such as anti-
hypertensive drugs or lipid-lowering drugs during the study.
Enzyme assays
The plasma  -galactosidase A activity was measured by
fluorometric assay using 10 mM 4-methyumbelliferyl- -D-
galactoside (Sigam-Aldrich, St. Louis, MO, U.S.A.) as a sub-
strate. Leukocytes were isolated from peripheral blood col-
lected in an EDTA tube. After sonication with Virsonic100
(Virtis, Gardiner, NY, U.S.A.), the leukocyte supernatant with
0.1 mL of the substrate was incubated at 37℃ for 30 min.
For preclusion of  -galactosidase B (GALB) activity, 0.1 M N-
acetylgalactosamine was added to the reaction mixture as an
inhibitor of GALB. Reactions were stopped by adding 1.3
mL of 0.17 M glycine-carbonate buffer at pH 9.8. The fluores-
cence at an excitation wavelength of 360 nm and an emission
wavelength of 415 nm was read. Normal ranges in our labo-
ratory were from 45 to 85 nmoles/hr/mg in leukocytes (13).
Measurement of plasma and urine GL-3 levels
Plasma and urine were prepared using a modification of the
Bligh-Dyer method (14). Plasma was mixed with distilled
water at a ratio of 1:4. A 5- L working internal standard solu-
tion of 2.5  g/mL C17:0 GL-3 was added, then 80% dioxane
was mixed into the solution, which was then vortex-mixed
for 30 sec and centrifuged at 12,000 rpm for 5 min. The upper
layer was transferred to an injection vial for tandem mass spec-
trometry (MS/MS) analysis. Urine was prepared as plasma in
a 1:50 dioxane dilution ratio. A diluted sample was used direct-
ly for acquisition of positive-ion electrospray ionization (ESI)
mass spectra. MS/MS after ESI was performed as the previously
described method after fast atom bombardment (FAB) ioniza-
tion (15). The 8 GL-3 isomers and C17:0 GL-3 were separated
on a C8 guard cartridge column (4×3 mm internal diameter;
phenomenex) prior to quantification by ESI-MS/MS. Normal
ranges for plasma GL-3 were from 3.88 to 9.87  g/mL and
for urine GL-3 were from 0.008 to 0.898  g/mg Cr. During
ERT, GL-3 levels were measured in plasma and urine every
3 months.
DNA analysis
Genomic DNA was isolated from peripheral blood leuko-
cytes using a Puregene DNA isolation kit (Gentra, Minneapo-
lis, MN, U.S.A.). Seven exons of GLA and their intronic flank-
ing sequences were amplified by polymerase chain reaction
(PCR) with seven sets of previously described primers, followed
by single-strand conformational polymorphism analysis and
direct sequencing (16). DNA sequencing was carried out using
the same primers used in PCR with a BigDye Terminator
V3.0 Cycle Sequencing Ready reaction kit (Applied Biosys-
tems, Foster city, CA, U.S.A.). Electrophoresis and analysis of
the reaction mixtures were performed on an ABI 3100 Genet-
ic analyzer (Applied Biosystems).
Histologic and ultrastructural studies of kidney pathologic
findings
Histologic and ultrastructural studies using standard pro-
cedures were employed to evaluate pathologic changes and the
degree of GL-3 deposition before and 1 yr after the first onset
of ERT. Kidney specimens were obtained in 3 out of 11 patients
by ultrasound-guided needle biopsy. Kidney biopsies were not
performed in the other patients due to their short follow-up
periods less than one year. The specimens for histological exam-
ination were fixed in Bouin fixative, embedded in paraffin, and
cut into 2  m sections. Subsequently, hematoxylin and eosin,
periodic acid-Schiff, periodic acid-silver methenamine, Luxol-
fast blue, and Masson’s trichrome staining were performed. For
electron microscopy, 2.5% gluteraldehyde-fixed tissues were
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at 50-80 nm, double-stained with uranyl acetate and lead cit-
rate, and examined under a JEOL 1200EX-II transmission
electron microscope. For the preparation of semi-thin sec-
tions, tissues were cut at 1  m and stained with toluidine
blue.
On ultrastructural studies, the vascular endothelial deposits
of GL-3 was scored from 0 to 3 as previously described (11):
0; no inclusions, trace, one small granule, 1; multiple dis-
crete granules, 2; single or multiple aggregates of granules,
3; aggregates of granules causing distortion of luminal en-
dothelial surface. Renal histology was examined by the same
pathologist in all three patients. Pathologist was blinded to
patient identities and the time points at which the specimens
had been obtained.
Treatment protocol
Agalsidase beta (Fabrazyme
�; Genzyme Corp., Cambridge,
MA, U.S.A.) was intravenously infused at a dose of 1 mg/kg
every 2 weeks. The enzyme was diluted in a 0.07 mg/mL of
concentration with normal saline and was administered at a
rate of 15 mg/hr. The duration of treatment ranged from 4 to
27 months.
Statistical methods
Statistical analyses were performed using SPSS version 12.0
for Windows. Changes before and after treatment were ana-
lyzed by a Wilcoxon signed rank tests. Differences in param-
eters at more than two treatment time points were analyzed
for significance using repeated measures ANOVA. p values
less than 0.05 were considered to be statistically significant.
RESULTS
Clinical manifestations (Table 1, 2)
The age at initial ERT ranged from 13 to 48 yr. Five out of
11 Fabry patients exhibited neurologic manifestations includ-
ing tinnitus, dizziness, and sensorineural hearing loss. The most
common presenting symptoms and signs were acroparesthe-
sia, hypohidrosis, and proteinuria. Patients 1, 6, and 7 have
received diphenylhydantoin and carbamazepine for pain relief.
Left ventricular hypertrophy was observed before ERT in 6
patients on electrocardiogram or echocardiogram. Corneal
clouding was observed in 9 patients on slit lamp examination.
All female carriers experienced acroparesthesias in childhood.
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Age at Age at Age at
Family
Symptoms and Basal Residual
Family Patient Sex onset diagnosis ERT
history
Type signs at plasma/urine enzyme, % of Genotype
(yr) (yr) (yr) diagnosis GL-3 ( g/mL) normal control
I 1 M 7 18 24 De novo Classic Acroparesthesia 17.79/0.75 0 p.L268fsX1
II 2 M 10 29 47 Familial Classic Anhidrosis 9.97/4.05 0 p.D266N
3 F 18 21 21 Familial Carrier Acroparesthesia 12.57/5.97 2.7 p.D266N
III 4 M 8 31 31 Familial Classic Acroparesthesia 14.82/15.11 0 p.R342X
IV 5 M 10 38 38 De novo Classic Renal failure 10.15/0.05 0 p.R112C
V 6 M 11 17 17 Familial Classic Acroparesthesia 16.04/7.00 0 p.T412Sfs38
7 M 10 20 20 Familial Classic Proteinuria 14.23/3.54 0 p.T412Sfs38
8 M 12 13 13 Familial Classic Acroparesthesia 10.84/9.97 0 p.T412Sfs38
9 F 15 48 48 Familial Carrier Acroparesthesia 7.24/0.23 16 p.T412Sfs38
10 F 20 44 44 Familial Carrier Acroparesthesia 8.63/0.71 10 p.T412Sfs38
VI 11 M 10 36 36 De novo Classic Proteinuria 15.32/7.15 0 p.M42V
Table 1. Clinical characteristics of patients with Fabry disease
Pediatric Fabry disease Female carriers Adult Fabry disease 
(Age at diagnosis <18 yr) (N=2) (N=3) (Age at diagnosis  18 yr) (N=6)
Number of patients on ERT 2 3 6
Duration of ERT (yr) 0.8-2 0.3-1.5 1.2-2.6
Age at diagnosis (yr) 13-17 21-48 18-38
Current age (yr) 14-18 22-49 22-49
Symptoms Acroparesthesia, corneal clouding, Acroparesthesia, corneal clouding, Renal failure, azotemia, proteinuria,
hypohidrosis, gastrointestinal left ventricular hypertrophy, sensorineural hearing loss, cardiovascular
symptoms (vomiting, diarrhea), microscopic hematuria, dysfunction, angiokeratoma
proteinuria, retarded growth hypohidrosis, leg edema ischemic changes on MRI brain
Table 2. Clinical and demographic profiles of the Korean Fabry registry
ERT, enzyme replacement therapy; MRI, magnetic resonance imaging.
ERT, enzyme replacement therapy; GL-3, globotriaosylceramide.They exhibited mild clinical manifestations such as neurono-
pathic pain, hypohidrosis, corneal clouding, and lymphedema
of legs. Two patients (patients 6 and 8) were diagnosed at pedi-
atric ages (13-17 yr of age) (Table 2). ERT has been initiated
as soon as they were diagnosed. Two pediatric patients man-
ifested with acroparesthesia, anhidrosis, left ventricular hyper-
trophy, corneal clouding, and gastrointestinal symptoms such
as vomiting and diarrhea. After one year of treatment, high-
frequency sensorineural hearing loss and tinnitus were not ame-
liorated in all affected patients. There was no remarkable im-
provement in angiokeratoma of the skin, corneal clouding, and
left ventricular hypertrophy.
Kidney function
Serum creatinine levels were normal, except for patient 5,
and remained stable throughout the treatment periods (Fig.
1A). Patient 5 was diagnosed with Fabry disease after kidney
transplantation, and his serum creatinine levels also remained
stable. Sequential changes in creatinine clearance revealed some
inter- and intra-individual variations during ERT. However,
these changes were statistically not significant (p>0.05) (Fig.
1B). Five patients had increased protein excretion of more than
150 mg/day before treatment. There were no significant
changes in the degree of proteinuria during ERT (p>0.05)
(Fig. 1C).
Plasma and urine GL-3
All patients exhibited increased plasma GL-3 levels, except
for two female heterozygotes. The GL-3 levels were reduced
to the normal range within 3 to 6 months of ERT onset, with
the exception of two patients (patients 4 and 11) (Fig. 2A).
Urine GL-3 levels were also elevated, but reduced significantly
within 6 to 9 months after ERT onset except patient 4 (Fig.
2B).
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Fig. 1. Renal function of patients during enzyme replacement therapy. Serum creatinine (A), creatinine clearance (B), and 24-hr urine
protein levels (C) remained stable without aggravation or improvement (p>0.05). Data are presented as mean±SD.
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Fig. 2. Sequential changes in the GL-3 concentration in plasma (A) and urine (B) during enzyme replacement therapy.
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11Histologic and ultrastructural studies of kidney (Table 3)
Pre- and post-treatment kidney biopsy findings were com-
pared in three patients (patients 1, 6, and 7). The histologic
features evaluated were summarized in Table 3. On patho-
logic examination, all patients revealed cytoplasmic foamy vac-
uolization and GL-3 deposition of podocytes, tubular epithelial
cells, endothelial cells, and vascular smooth muscle cells,
which are the characteristic pathologic features of Fabry dis-
ease. In patients 1 and 6, the GL-3 deposition was markedly
decreased in the vascular endothelial cells after ERT, although
the glomerular and tubulointerstitial features were not changed
(Fig. 3). However, in patient 7, the GL-3 deposition in the vas-
cular endothelial cells was not decreased and the glomerular
and tubulointerstitial changes were advanced.
Adverse events
Two patients (patients 3 and 7) experienced mild fever and
chest tightness as infusion-association reactions on their first
infusion. They have been on a regular pre-infusion medica-
tion including acetaminophen and hydroxyzine to prevent infu-
sion reactions and these symptoms were relieved by pre-infu-
sion medication.
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Pathologic findings
Patient 1 Patient 6 Patient 7
Pre Post Pre Post Pre Post
Glomeruli Number 25 37 30 22 7 22
Foamy vacuolization 3 3 3 3 3 3
Mesangial widening 1 1 0 0 0 1
Segmental sclerosis 0 0 0 0 1 1
Global sclerosis 1 1 0 0 0 1
Interstitium Inflammation 0 0 0 0 0 1
Fibrosis 0 0 0 0 0 1
Tubules Foamy vacuolization 1 1 1 1 1 1
Atrophy 0 0 0 0 0 1
Vessels Hyalinosis 0 0 0 0 0 1
Intimal fibrosis 2 1 0 0 1 1
GL-3 deposition 3 1 3 1 1 1
Table 3. Histology and ultrastructural studies of kidney patho-
logic findings of patients with Fabry disease; Changes in indi-
vidual scores for globotriaosyleramide (GL-3) deposits of kid-
ney specimens from baseline to after 1 yr of infusion
Fig. 3. Pathologic features before (A, C) and after (B, D) ERT. No significant changes were identified the glomerulus and tubulointerstitium on
histologic examination. However, the vascular endothelial GL-3 depositions (arrows) were markedly decreased after the ERT (from patient 1;
A and B, PAS staining at ×400 magnification; C and D, toluidine blue staining of semithin sections at ×1,000 magnification).
A B
C D
Pre ERT One tear post ERTDISCUSSION
This is the first report of ERT in Korean patients with Fabry
disease. The wide spectrum of clinical and laboratory find-
ings documented in this study were similar to previous reports
in most of the males and females (17, 18). Although the peri-
od of treatment and the age of the subjects vary consider-
ably, ERT is safe and effective in stabilizing renal functions,
decreasing GL-3 levels in plasma and urine, and clearing GL-
3 deposits from kidney biopsy specimens without significant
adverse events in patients with Fabry disease.
Fabry disease is diagnosed by demonstration of deficient
-galactosidase A activity in plasma or leukocytes and muta-
tion analysis of the GLA gene. Patients with residual enzyme
activity have a milder, variant phenotype (19). In female het-
erozygotes, a very low  -galactosidase A level is also diagnostic
of the carrier state. However, normal or near-normal enzyme
activity does not rule out the possibility that a female is a car-
rier because of random X-chromosomal inactivation. Thus, all
girls and women at risk for carrying the disease gene should
be determined their status by molecular studies (20).
The  -galactosidase A is encoded by the GLA gene that con-
tains 7 exons located on Xq22.1 (21). Over 350 mutations
have been identified in the Human Gene Mutation Database
(http://www.hgmd.org/). Six different mutations of the GLA
gene have been identified in 6 families of Fabry disease (Table
1). Two mutations (p.L268fsX1 and p.D266N) were previ-
ously reported as novel by the authors (22). The mutations in
three patients (patients 1, 5, and 11) were de novo without
mutations of the GLA gene in other family members. Genetic
counseling should be provided to inform other family mem-
bers of the availability of diagnostic testing and early treat-
ment. The periods from the onset of symptoms to the ages
of diagnosis ranged from 1 to 33 yr.
The optimal goal of ERT is to preserve normal renal func-
tion by early clearance of GL-3 endothelial deposits and pre-
vention of further deposits (23). Clinical trials have demonstrat-
ed the safety and effectiveness of ERT (11). ERT resulted in
decreased plasma and urine GL-3 levels even after a short-term
treatment, and reduced GL-3 accumulation in various organs
and tissues (24). Elevations and changes in urine glycolipids
were less pronounced in heterozygotes and in recipients of a
renal allograft (25). It admits no doubt that ERT should be
initiated in carriers with substantial disease manifestations as
well as all affected male patients with Fabry disease as early
as possible to prevent irreversible major organ damage (12,
26-28). ERT was safe and effective in clearing of GL-3 and
improvement of autonomic function in children with Fabry
disease (29). Urinary excretion of GL-3 has not been reduced
except in patient 4, although his renal function has remained
stable during ERT. Long-term follow-up is needed for the
evaluation of effects on urinary GL-3 excretion in this patient.
Clinical symptoms, such as acroparesthesia, pain crisis, hypo-
hidrosis, and diarrhea, have been reported to be improved by
ERT (30). Improvement of pain and anhidrosis was not assessed
in this report due to its subjective nature and relatively short-
term follow-up periods to evaluate the effectiveness to neuro-
logic symptoms. Although pain scores were not assessed, pain
crisis in patient 1 decreased during ERT. Angiokeratoma did
not change after 24 months of ERT (30). In this report, corneal
clouding, angiokeratoma, acroparesthesia, and sensorineural
hearing loss did not change during ERT. Although there are
a few reports on the effects of ERT on sensorineural hearing
loss, it appears to be reversed after long-term ERT (31, 32).
Pure tone audiometry should be followed-up in these patients
after long-term treatment. The major limitation of the use of
ERT for Fabry disease is the inability of large molecules such
as enzymes to cross the blood-brain barrier (33). Therefore, it
is controversial as to whether the use of ERT could improve
central nervous system manifestations. Six patients with left
ventricular hypertrophy did not reveal any change their elec-
trocardiogram or echocardiogram findings during short-term
ERT. Cardiac contractility and left ventricular mass improved
after 18 months of ERT in kidney transplant patients (34).
There were no significant changes in renal function during
short-term treatment periods in this study. The clinical efficacy
of ERT was associated with stabilization of renal function, a
significant reduction in the GL-3 level, and improvement in
renal pathology (34). Therefore, ERT is recommended in pa-
tients who received renal transplantation to improve quality
of life and to prevent cardiac and cerebrovascular complica-
tions (26, 30). Patient 5 has been treated with ERT after renal
transplantation without significant adverse effects or any com-
plications of Fabry disease. Previous studies have also demon-
strated that ERT stabilized renal function after 30 months
of an open-label extension trial study (12). Renal pathologic
findings in this study also revealed persistent GL-3 deposits
in podocytes. Despite decreased plasma and urine GL-3 lev-
els, there were no significant changes in urinary protein excre-
tion and serum creatinine levels.
The occurrence of immunoglobulin G antibodies results in
hypersensitivity reactions in some patients, necessitating reduc-
tion in the rate of infusion time and/or the use of premedica-
tions such as antihistamines or corticosteroids (11, 34). Al-
though the vast majority of patients on agalsidase beta treat-
ment develop antibodies, antibodies against agalsidase were
not measured in this study. Whether the inhibition of recom-
binant human  -galactosidase A activity by IgG antibodies
has a significant clinical effect or not is unclear (35). Infusion-
associated reactions have been observed in two patients, which
were easily treated with acetaminophen and hydroxyzine.
In summary, this study demonstrates that the clinical effects
of ERT were associated with a significant reduction in the serum
and urine GL-3 levels, and clearance of the accumulated GL-
3 from the vascular endothelium of biopsied kidney. It is antic-
ipated that ERT will stabilize the disease and preserve kidney
function, thereby preventing the cardiac and cerebrovascular
complications in patients with Fabry disease. Therefore, ERT
248 J.-H. Choi, Y.M. Cho, K.-S. Suh, et al.should be initiated as early as possible in affected males and
symptomatic carrier females before irreversible damage has
occurred.
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